Staffing: 2024’s Biggest Lab Operations Challenge
ADLM president Anthony Killeen looks at labs’ staffing struggles in 2024 and what can be done to alleviate them in the coming year
Keeps You Up-to-Date on Lab Business and Competitive Strategy, Market Trends and Opportunities, and M&A and Investment Activity in Today’s Diagnostic Lab Industry
ADLM president Anthony Killeen looks at labs’ staffing struggles in 2024 and what can be done to alleviate them in the coming year
The bill is designed to provide Medicare patients faster access to innovative technology approved by the FDA.
April was among the busiest months, in recent memory, in terms of both deal volume and significance in the diagnostics industry.
No company better embodies the vicissitudes of running a COVID-19-focused diagnostics business during the pandemic period than Lucira Health.
HHS secretary takes action to ensure that EUAs remain in effect until the “significant potential” for a COVID-19 PHE no longer exists.
Product integration collaborations have become increasingly common, with five such deals being announced between February and mid-March.
While only time will tell how bad the ultimate damage turns out to be, it appears for now at least that the industry has dodged a bullet.
Carl Icahn has decided to take his beef with Illumina’s board of directors over the acquisition directly to company shareholders.
Agency’s annual report to Congress concludes that providers are doing just fine and don’t need a big bump in pay at this time.
The deal closed Feb.22, but the FTC has expressed concerns about the acquisition and Amazon’s business practices in general.
With COVID-19 testing demand all but dried up, labs will have to make—or at least contemplate making—significant changes to their business.